Ingrid Tein

Ingrid Tein

Auto-generated profile, based on publicly available information

Ingrid Tein

Division of Neurology, Dept. of Pediatrics and Dept. of Laboratory Medicine and Pathobiology, The Genetics and Genome Biology Program, The Research Institute, The Hospital for Sick Children, The University of Toronto, Toronto, Ontario, Canada M5G 1X8

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2003 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
ITI. Tein
I. Tein

25 May 2010 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
ALAnne‐Marie Lamhonwah
Anne‐Marie Lamhonwah
CBChristine E. Bear
Christine E. Bear
LHLing Jun Huan
Ling Jun Huan
PCPatrick Kim Chiaw
Patrick Kim Chiaw
CACameron A. Ackerley
Cameron A. Ackerley
ITIngrid Tein
Ingrid Tein

1 February 2008 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
ITIngrid Tein
Ingrid Tein
OEOrly Elpeleg
Orly Elpeleg
BBBruria Ben-Zeev
Bruria Ben-Zeev
SKStanley H. Korman
Stanley H. Korman
ALAlexander Lossos
Alexander Lossos
NGNiels Gregersen
Niels Gregersen

20 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LRLance H. Rodan
Lance H. Rodan
GWGreg D. Wells
Greg D. Wells
LBLaura Banks
Laura Banks
STSara Thompson
Sara Thompson
JSJane E. Schneiderman
Jane E. Schneiderman
ITIngrid Tein
Ingrid Tein
To study the effects of L-arginine (L-Arg) on total body aerobic capacity and muscle metabolism as assessed by 31Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) in patients with MELAS (Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes) syndrome. We performed a case control study in 3 MELAS siblings (m.3243A>G tRNAleu(UUR) in MTTL1 gene) with different % blood mutant mtDNA to evaluate total body maximal aerobic capacity (VO2peak) using graded cycle ergometry and muscle metabolism using 31P-MRS. We then ran a clinical trial pilot study in MELAS sibs to assess response of these parameters to single dose and a 6-week steady-state trial of oral L-Arginine. At baseline (no L-Arg), MELAS had lower serum Arg (p = 0.001). On 31P-MRS muscle at rest, MELAS subjects had increased phosphocreatine (PCr) (p = 0.05), decreased ATP (p = 0.018), and decreased intracellular Mg2+ (p = 0.0002) when compared to matched controls. With L-arginine therapy, the following trends were noted in MELAS siblings on cycle ergometry: (1) increase in mean % maximum work at anaerobic threshold (AT) (2) increase in % maximum heart rate at AT (3) small increase in VO2peak. On 31P-MRS the following mean trends were noted: (1) A blunted decrease in pH after exercise (less acidosis) (2) increase in Pi/PCr ratio (ADP) suggesting increased work capacity (3) a faster half time of PCr recovery (marker of mitochondrial activity) following 5 minutes of moderate intensity exercise (4) increase in torque. These results suggest an improvement in aerobic capacity and muscle metabolism in MELAS subjects in response to supplementation with L-Arg. Intramyocellular hypomagnesemia is a novel finding that warrants further study. Class III evidence that L-arginine improves aerobic capacity and muscle metabolism in MELAS subjects. ClinicalTrials.gov NCT01603446.

1 April 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ZZZarazuela Zolkipli-Cunningham
Zarazuela Zolkipli-Cunningham
CPChristina B. Pedersen
Christina B. Pedersen
ALAnne-Marie Lamhonwah
Anne-Marie Lamhonwah
NGNiels Gregersen
Niels Gregersen
ITIngrid Tein
Ingrid Tein
To elucidate the pathophysiology of SCAD deficient patients who have a unique neurological phenotype, among fatty acid oxidation disorders, with early developmental delay, CNS malformations, intractable seizures, myopathy and clinical signs suggesting oxidative stress. We studied skin fibroblast cultures from patients homozygous for ACADS common variant c.625G>A (n = 10), compound heterozygous for c.625G>A/c.319C>T (n = 3) or homozygous for pathogenic c.319C>T (n = 2) and c.1138C>T (n = 2) mutations compared to fibroblasts from patients with carnitine palmitoyltransferase 2 (CPT2) (n = 5), mitochondrial trifunctional protein (MTP)/long-chain L-3-hydroxyacyl-CoA dehydrogenase (LCHAD) (n = 7), and medium-chain acyl-CoA dehydrogenase (MCAD) deficiencies (n = 4) and normal controls (n = 9). All were exposed to 50 µM menadione at 37°C. Additonal conditions included exposure to 39°C and/or hypoglycemia. Time to 100% cell death was confirmed with trypan blue dye exclusion. Experiments were repeated with antioxidants (Vitamins C and E or N-acetylcysteine), Bezafibrate or glucose and temperature rescue. The most significant risk factor for vulnerability to menadione-induced oxidative stress was the presence of a FAO defect. SCADD fibroblasts were the most vulnerable compared to other FAO disorders and controls, and were similarly affected, independent of genotype. Cell death was exacerbated by hyperthermia and/or hypoglycemia. Hyperthermia was a more significant independent risk factor than hypoglycemia. Rescue significantly prolonged survival. Incubation with antioxidants and Bezafibrate significantly increased viability of SCADD fibroblasts. Vulnerability to oxidative stress likely contributes to neurotoxicity of SCADD regardless of ACADS genotype and is significantly exacerbated by hyperthermia. We recommend rigorous temperature control in SCADD patients during acute illness. Antioxidants and Bezafibrate may also prove instrumental in their management.

21 March 2015 in Mitochondrion
Verified
Journal Article
Closed access
LRL.H. Rodan
L.H. Rodan
JPJ. Poublanc
J. Poublanc
JFJ.A. Fisher
J.A. Fisher
OSO. Sobczyk
O. Sobczyk
TWT. Wong
T. Wong
ITI. Tein
I. Tein